Table 2.
GEP testing and the receipt of adjuvant chemotherapy
| Clinical Recurrence Risk | ||||
|---|---|---|---|---|
| All Patients | Low | Moderate | High | |
| n | 534 | 60 | 204 | 253 |
| Received Chemotherapy | 364 (68.2%) | 6 (10.0%) | 115 (56.4%) | 234 (92.5%) |
| Received GEP test | 138 (25.8%) | 15 (25.0%) | 106 (52.0%) | 14 (5.5%) |
| Received Chemotherapy among those who had a GEP test | 69 (50.0%) | 5 (33.3%) | 53 (50.0%) | 9 (64.3%) |
| Odds Ratio for Receipt of Chemotherapy (95% confidence interval) | ||||
| Received GEP test | ||||
| Unadjusted | 0.34 (0.23 – 0.51) |
22.00 (2.31 – 209.6) |
0.58 (0.33 – 1.02) |
0.11 (0.03 – 0.38) |
| Adjusted for propensity to receive a GEP test |
0.62 (0.39 – 0.99) |
42.19 (2.50 – 711.82) |
0.64 (0.36 – 1.14) |
0.12 (0.03 – 0.47) |
NOTES: Reference in adjusted analyses is women who did not receive a GEP test. Propensity score methods were used to control for confounding by characteristics that may be associated with receipt of a GEP test. Each woman’s propensity to receive a GEP test was estimated as a function of her age at diagnosis, comorbidity score, year of diagnosis, tumor size, grade, nodal status, estrogen and progesterone receptor status, and HER2 receptor status, and was categorized in tertiles in adjusted model.